Expanded-access for the Use of Setemelanotide in a Single Patient With Partial Lipodystrophy (LD) Associated With Leptin Deficiency and Multiple Autoimmune Diseases

Trial Profile

Expanded-access for the Use of Setemelanotide in a Single Patient With Partial Lipodystrophy (LD) Associated With Leptin Deficiency and Multiple Autoimmune Diseases

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Setmelanotide (Primary)
  • Indications Hypertriglyceridaemia; Lipodystrophy
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Rhythm
  • Most Recent Events

    • 29 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top